Entries |
Document | Title | Date |
20080207746 | Intracorporeal medicaments for photodynamic treatment of disease - New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles. | 08-28-2008 |
20080227852 | SCHWEINFURTHIN ANALOGUES - Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs. | 09-18-2008 |
20080255224 | PHARMACOLOGICAL TREATMENT OF PSORIASIS - The present invention relates generally to the prevention and treatment of psoriasis and psoriatic-related skin conditions via administration of a cannabinoid agonist, especially nabinone, either alone or in combination with other agents that possess anti-psoriatic pharmacological activity. | 10-16-2008 |
20080262079 | Cannabinoid Compositions and Methods of Use Thereof - The present invention provides cannabinoid compositions and the use of such cannabinoid compositions in the treatment of autoimmune and/or inflammatory diseases and disorders. For example, the present invention provides a method of using tetrahydrocannabinoid (THC) compounds in the treatment of autoimmune and/or inflammatory diseases and disorders. | 10-23-2008 |
20090042974 | Compositions And Methods Relating To Extensible Transgenic Vector Assembler, Pestilence Ridder, Plus Cannabinoid Producer - The following provisional patent application refers to the methods and compositions relating to a novel use for enzymatic catalysis of C21-H30-O2 (delta-nine tetrahydrocannabinol (THC)) as an insect repellent, bactericide, and fungicide and dispensation methods as commercial reagent. | 02-12-2009 |
20090099254 | Method and Kit for Regulation of Microvascular Tone - Methods and kits for regulating arterial microvascular tone in which a composition comprising a COX-2 inhibitor and a cannabinoid receptor agonist are administered to a subject. | 04-16-2009 |
20090170926 | Antiviral agents - The present invention provides a method of treatment or prophylaxis of hepatitis B virus in a subject comprising administering an effective amount of a compound of formula ( | 07-02-2009 |
20090176869 | Halogenated Rhodamine Derivatives and Applications Thereof - Compounds of formula I: | 07-09-2009 |
20090197941 | Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease - The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC. | 08-06-2009 |
20090221691 | COMPOSITIONS AND METHODS FOR INHIBITING G PROTEIN SIGNALING - The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of a G protein are also provide. | 09-03-2009 |
20090221692 | CB2 RECEPTORS BLOCKS ACCUMULATION OF HUMAN HEPATIC MYOFIBROBLASTS: A NOVEL ANTIFIBROGENIC PATHWAY IN THE LIVER - Methods for treating diseases of the livers mediated by CB2 receptors are described. The methods may include administering an effective amount of a cannabinoid, an agent that activates a CB2 receptor, a composition that includes a non-selective agonist of CB2 and a selective antagonist of CB1, a composition that includes an agonist of CB2 receptors, and/or a composition that includes an up-regulator of CB2 receptors to a patient who has liver fibrosis. | 09-03-2009 |
20090247619 | Cannabinoid-Containing Compositions and Methods for Their Use - This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition. | 10-01-2009 |
20090253782 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof - The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof. | 10-08-2009 |
20090253783 | Production of Delta 9 Tetrahydrocannabinol - The present invention provides isolated, purified Δ9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. | 10-08-2009 |
20090275648 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, cardiovascular disorders, obesity and obesity-associated disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 11-05-2009 |
20090275649 | Compositions And Methods For Identifying Modulars Of TRPV2 - It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2. | 11-05-2009 |
20090292011 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES - Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 11-26-2009 |
20090298929 | NOVEL NATURAL CYCLODEXTRIN COMPLEXES - The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of α-CD, β-CD and γ-CD and a cannabinoid selected from the classical cannabinoid-group consisting of canabinol, tetrahydrocanabinol and canabidiol. | 12-03-2009 |
20100016418 | Cannabinoids for use in the treatment of neuropathic pain - The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts. | 01-21-2010 |
20100022631 | Treatment of hepatic encephalopathy and liver cirrhosis - The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis. | 01-28-2010 |
20100035978 | COMBINATION OF CANNABINOIDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN - The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10. | 02-11-2010 |
20100069475 | METHOD OF ACTIVATING NK CELLS - The present invention provides a method of mediating hypo-activation of NK cells. Methods of the present invention comprise administering to a subject an effective amount of broad acting phosphotase inhibitor, such as sodium orthovanadate, SHP specific inhibitor. In one embodiment, the SHP specific inhibitor is NSC119910. | 03-18-2010 |
20100120903 | Anti-inflammatory agent - An anti-inflammatory agent which includes an oil-soluble licorice extract, prepared by subjecting at least one of a leguminous plant of the genus | 05-13-2010 |
20100144854 | USE OF RHODAMINE 6G AS A MEDICINAL AGENT FOR TREATING MALIGNANT NEOPLASMS AND AMILOIDOSES - Rhodamine 6G is used as a medical agent for treating malignant neoplasms and amyloidoses at a dosage ranging from 1 mg to 10 g in the form of an aqueous, physiological, or alcoholic solution. For different purposes, the rhodamine G6 solution is orally administered before or after meals, or rhodamine G6 solution is rectally administered or the rhodamine G6 1% solution is intravenously injected, or the rhodamine G6 is administered in the form if a suppository or a 1-5% ointment. | 06-10-2010 |
20100152283 | TETRAHYDROCANNABINOL MODULATORS OF CANNABINOID RECEPTORS - The present invention relates to new tetrahydrocannabinol modulators of cannabinoid receptors, pharmaceutical compositions thereof, and methods of use thereof. | 06-17-2010 |
20100184848 | TRANSDERMAL FORMULATIONS OF SYNTHETIC CANNABINOIDS AND NANO COLLOIDAL SILICA - The present invention relates to pharmaceutical compositions comprising cannabinoids or mimics thereof. In one aspect, the invention provides transdermal formulations comprising cannabinoids or mimics thereof. In another aspect, the invention provides topical formulations comprising cannabinoids or mimics thereof. In one embodiment the formulations and compositions of the invention comprise nano colloidal silica. The formulations of the invention can be used in the therapeutic treatment of many conditions, including wherein the cannabinoids or mimics thereof are known to reduce the excessive neuronal firing characteristic of neuropathic pain. Muscle spasticity is also benefited by these formulations. | 07-22-2010 |
20100184849 | UREA OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6; A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n; Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra. | 07-22-2010 |
20100216872 | PLANT EXTRACT FROM LOW-THC CANNABIS FOR THE TREATMENT OF DISEASE - The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of | 08-26-2010 |
20100249223 | NEW USE FOR CANNABINOID-CONTAINING PLANT EXTRACTS - The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel. Preferably the diseases or conditions to be prevented or treated include neuropathic pain, inflammation or vasoconstriction. | 09-30-2010 |
20100317729 | NEW PHARMACEUTICAL FORMULATION COMPRISING CANNABIDIOL AND TETRAHYDROCANNABIDIVARIN - The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB | 12-16-2010 |
20100317730 | Treatment for menopausal and perimenopausal vasomotor symptons - Disclosed is a medicinal composition and method of use comprising topiramate for treating hot flashes and excessive sweating known as vasomotor symptoms related to perimenopausal or menopausal symptoms and in a still further embodiment of the invention topiramate and the medicine for treating menopause and perimenopause are provided in a kit or in unit dosage form, e.g., tablet or capsule. As a further embodiment of this invention, topiramate may be administered along with a medicament use to treat hot flashes and excessive sweating related to perimenopausal or menopausal symptoms. | 12-16-2010 |
20100317731 | Hyperhidrosis treatment - Disclosed is a medicinal composition and method of use conspiring topiramate for treating drug-induced excessive sweating (hyperhidrosis). As a further embodiment of this invention, topiramate may be administered along with another medicament that causes excessive sweating to prevent such excessive sweating. As still a further embodiment of this invention, topiramate may be administered along with another medicament that treats excessive sweating, such that the synergy of the drugs effectively treats the sweating. | 12-16-2010 |
20100317732 | METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS - Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R | 12-16-2010 |
20110021616 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF - Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. Examples of rhodamine compounds include 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4′, 5′-dichloro-benzoic acid methyl ester hydrochloride; 4,5-dibromorhodamine 110 2-(2-methoxy ethoxy)ethyl ester hydrobromide; acetate salt of 2,7-dibromorhodamine B hexyl ester; acetate salt of 2,7-dibromorhodamine B methyl ester; 4,5-dibromorhodamine 6G hydrobromide; rhodamine B 3-bromopropyl; acetate salt of 2,7-dibromo-4′-carboxytetramethylrosamine methyl ester; 4-bromo-5-phenyl rhodamine B methyl ester chloride; 2,7-dibromo-4,5-dimethyl rhodamine B methyl ester bromide; 2-bromo-7-ethynyl rhodamine B methyl ester bromide; and 4,5-dibromo-2,7-di-n-butyl rhodamine B methyl ester bromide. | 01-27-2011 |
20110021617 | Medicinal Acidic Cannabinoids - The invention relates to an acidic cannabinoid for medical use and to a | 01-27-2011 |
20110046213 | Production of Delta 9 Tetrahydrocannabinol - Δ9 THC is obtained by extracting Δ9 THC and Δ9 THC carboxylic acid from plant material using a non-polar solvent and decarboxylating the Δ9 THC acid into Δ9 THC in the same solvent, without a solvent swap, in the presence of aqueous base. The Δ9 THC is then washed to remove inorganic impurities, still in the same original solvent. | 02-24-2011 |
20110071217 | Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isoben- zofuran-1,9'-xanthen]-3-one (Rose Bengal) and Related Xanthenes - A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments. | 03-24-2011 |
20110071218 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF - The disclosure relates to novel compounds of the formula (I) R | 03-24-2011 |
20110082195 | NEW USE FOR CANNABINOIDS - The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease. | 04-07-2011 |
20110092583 | Oral Dosage Form Of Tetrahydrocannabinol And A Method Of Avoiding And/Or Suppressing Hepatic First Pass Metabolism Via Targeted Chylomicron/Lipoprotein Delivery - Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron/lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic/non-amphiphilic solutes to induce semi-solid formation for targeted release rates. | 04-21-2011 |
20110112182 | DESIGN, SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF ROTTLERIN ANALOGS - A method of synthesizing rottlerin analogs is described. The synthesis methods described are the first known method of synthesizing rottlerin analogs from commercially-available materials to produce cost effective analogs. Rottlerin analog structures made by the synthesis methods and methods of use for treating a neurological or inflammatory response mediated by protein kinase C (PKC) are further described. | 05-12-2011 |
20110160297 | SCHWEINFURTHIN ANALOGUES - The invention provides fluorescent schweinfurthin analogs of formula(I) which are useful as probes and for the treatment of cancer and other diseases. | 06-30-2011 |
20110230549 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN - The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC. | 09-22-2011 |
20110257256 | CANNABINOIDS FOR USE IN TREATING OR PREVENTING COGNITIVE IMPAIRMENT AND DEMENTIA - The present invention is directed to the use of at least one cannabinoid in the manufacture of a medicament for use in treating or preventing or in the manufacture of a dietary supplement for preventing a disease or condition benefiting from a reduced activity of the enzyme indoleamine 2,3-dioxygenase (IDO). The disease or condition to be treated or prevented is preferably selected from cognitive impairment or any kind of dementia. | 10-20-2011 |
20110257257 | COMPOSITION FOR TREATMENT OF EPITHELIAL TISSUE - A pharmaceutical composition is provided. The composition is a topical oil-in-water formulation which includes a GABA agonist such as topiramate as the active ingredient. | 10-20-2011 |
20110306660 | LIQUID CANNABINOID FORMULATIONS - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 12-15-2011 |
20110319481 | SCHWEINFURTHIN ANALOGUES - Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs. | 12-29-2011 |
20120010279 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 01-12-2012 |
20120046351 | Medicinal cannabis added in food - The invention is a product and a process wherein cannabinoids such as Medicinal Δ | 02-23-2012 |
20120046352 | Controlled cannabis decarboxylation - The invention is a process for the controlled decarboxylation of cannabis wherein Medicinal Delta-9 tetrahydrocannabinol (Δ | 02-23-2012 |
20120095087 | ENHANCED PRODUCTS BY SUSTAINABLE PROCESSES FOR MEDICINAL USE - A process for producing a composition with bioactive and/or bioavailable Cannabis-derived cannabinoids known to be effective for CB1 and/or CB2 modulation, and a plurality of indications for patients in need. Using a heat cycle process to combine cannabinoids, including but not limited to THC and CBD with flax seed oil and at least one of the triglycerides therein, an extract is formulated which enables substantially profiled and Cannabinoid ratio-balanced aliquots (“miquots”) to be offered for consideration to patients, including non-psychoactive topically and orally delivered products and systems. | 04-19-2012 |
20120095088 | Medicinal cannabis uniform in food - The invention is a product and a process wherein cannabinoids such as Medicinal Δ | 04-19-2012 |
20120095089 | SCHWEINFURTHINS AND USES THEREOF - Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula. | 04-19-2012 |
20120122966 | USE OF ORGANIC DYES AS ANALGESIC AGENTS - An organic dye from the group of crystal violet, gentian violet, malachite green oxalate and rhodamine 6G used as an analgesic agent in the form of a solution with the agent dosage ranging from 0.000001 mg to 10 g per intake. It is preferable to take the agent at least two times a day. In particular cases of use the agent is administered by mouth in the form of an aqueous solution before or after meals, or it is administered per rectum in the form of an aqueous solution, or a 1% solution of the agent is administered intravenously, or the agent is used in the form of a 1-5% ointment, or the agent is administered per rectum in the form of suppositories, and when arresting cancer pain the agent is injected into the tumor (under the tumor) or into a metastasis. Herein, one uses as analgesic agents widely available and inexpensive substances that are non-toxic, have no allergic effects and cause no addiction (dependence) when used in pharmaceutically acceptable doses; the treatment time is reduced, treatment efficiency is enhanced, and pain relief is provided while preserving patients' functional activity, using the minimum arsenal of analgesic agents with different effects, and completely eliminating the need for opiates. | 05-17-2012 |
20120165402 | USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY - This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. | 06-28-2012 |
20120190735 | Cancer Cell Apoptosis - There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent. | 07-26-2012 |
20120220650 | FUNCTIONAL MICROBIALLY FERMENTED TEA EXTRACT CONTAINING POLYPHENOL DERIVATIVE AND METHOD FOR PRODUCING THE SAME - A functional microbially fermented tea extract containing a novel polyphenol derivative and a method for producing the same are provided. A functional microbially fermented tea extract containing various extracts and a novel polyphenol derivative is produced by subjecting, to an extraction treatment, a microbially fermented tea leaf obtained by culturing one species selected from | 08-30-2012 |
20120245224 | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts. | 09-27-2012 |
20120252885 | DRONABINOL TREATMENT FOR MIGRAINES - In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions to treat migraines. | 10-04-2012 |
20120264818 | Topical Compositions with Cannabis Extracts - Various topical compositions including heat-treating mature, dried, powdered Cannabis sativa flower and bud leaves in carriers are disclosed. Various methods for the treatment of pain and methicillin-resistant | 10-18-2012 |
20120277296 | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease - The present invention relates to selective CB2 agonists for use in the prevention or treatment of alcoholic liver disease and particularly alcoholic hepatic steatosis and liver inflammation, and pharmaceutical composition thereof. | 11-01-2012 |
20120289589 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives - This invention discloses cannabinoid derivatives and pharmaceutical uses thereof. | 11-15-2012 |
20120295968 | Pharmaceutical Composition Comprising Cannabinoids - The present invention relates to a pharmaceutical composition comprising Δ9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof. | 11-22-2012 |
20120309820 | METHODS OF TREATING FIBROTIC DISEASES USING TETRAHYDROCANNABINOL-11-OIC ACIDS - This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions. | 12-06-2012 |
20120322866 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 12-20-2012 |
20130012575 | PLANT EXTRACT FROM LOW-THC CANNABIS FOR THE TREATMENT OF DISEASE - The present invention relates to a plant extract from a low-tetrahydrocannabinol (THC) variety of | 01-10-2013 |
20130109747 | PHARMACEUTICAL FORMULATION | 05-02-2013 |
20130116313 | Compositions and Methods for Inhibiting G Protein Signaling - The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of a G protein are also provided. | 05-09-2013 |
20130203843 | MILD CATIONIC MITOCHONDRIAL UNCOUPLERS - The present invention relates to biology and medicine and in particular can be used in medicine for the preparation of a pharmaceutical composition for the specific, self-regulating uncoupling of mitochondria. The invention can be useful in the treatment of diseases and conditions associated with the disruption of cellular metabolism, in the treatment of obesity, including pathological forms thereof, and also for the treatment of diseases associated with the increased formation of free radicals and reactive oxygen species. | 08-08-2013 |
20130231385 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 09-05-2013 |
20130245109 | PHARMACEUTICAL FORMULATION - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. | 09-19-2013 |
20130245110 | USE FOR CANNABINOIDS - The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease. | 09-19-2013 |
20130245111 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES - Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 09-19-2013 |
20130253046 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 - Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition. | 09-26-2013 |
20130274321 | Topical Compositions with Cannabis Extracts - The present invention provides a method for a topical treatment of a skin cyst. The method includes: applying a formulation to the skin cyst of a mammal; wherein the formulation includes: a dimethyl sulfoxide extract of mature, dried, powdered | 10-17-2013 |
20130274322 | Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isoben- zofuran-1,9'-xanthen]-3-one(Rose Bengal) and Related Xanthenes - A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100° C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments. | 10-17-2013 |
20130281523 | LOW DOSE CANNABINOID MEDICAMENTS - The present invention provides methods for treating cannabinoid-sensitive disorders with a lose-dose oral cannabinoid which results in delivery of a therapeutic level during an extended clinically-relevant therapeutic window. These methods provide therapeutic dosing while maintaining safe, side effect sparing, levels of a cannabinoid. The present invention also provides methods of determining optimal dosing in treated patients. | 10-24-2013 |
20130296415 | Manufacturing and Packaging Room Temperature Stable Dronabinol Capsules - The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention. | 11-07-2013 |
20130338220 | COMPOSITIONS, DOSAGES, AND METHODS OF USING TETRAHYDROCANNABINOL DERIVATIVES - Dosage forms of compounds of formula I, e.g., ajulemic acid, and methods of delivering these compounds and using these compounds to treat or prevent a CB1/CB2 associated disease are disclosed. | 12-19-2013 |
20130345299 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 12-26-2013 |
20140051751 | ENVIRONMENT-FRIENDLY ANTIFOULANTS FOR THE PREVENTION OF BIOFOULING - Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective. | 02-20-2014 |
20140066497 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES - This invention discloses cannabinoid derivatives and pharmaceutical uses thereof. | 03-06-2014 |
20140094511 | Treatment of Obstructive Sleep Apnea Syndrome with a Combination of a Carbonic Anhydrase Inhibitor and an Additional Active Agent - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 04-03-2014 |
20140100269 | ORAL CANNABINOID FORMULATIONS - Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability. | 04-10-2014 |
20140107192 | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. | 04-17-2014 |
20140194499 | Polyprenylated Benzoylphloroglucinols With Anticancer Activity - Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones A and C, are disclosed in the present invention. Garciesculentones A and C exhibit cytotoxicity and/or antimigration effect against various cancer cell lines. The experimental results of the present invention suggest that Garciesculentones A and C are useful for developing into anticancer drugs. | 07-10-2014 |
20140221469 | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use. | 08-07-2014 |
20140256803 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 09-11-2014 |
20140315991 | COMPOSITION FOR TREATMENT OF EPITHELIAL TISSUE - A pharmaceutical composition is provided. The composition is a topical oil-in-water formulation which includes a GABA agonist such as topiramate as the active ingredient. | 10-23-2014 |
20140329895 | OLIGOMER-CANNABINOID CONJUGATES - The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds. | 11-06-2014 |
20140343136 | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES - The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease. | 11-20-2014 |
20140357708 | ORAL DOSAGE FORM OF TETRAHYDROCANNABINOL AND A METHOD OF AVOIDING AND/OR SUPPRESSING HEPATIC FIRST PASS METABOLISM VIA TARGETED CHYLOMICRON/LIPOPROTEIN DELIVERY - An oral dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) about 15 to 85 wt % of one or more triglycerides formed from long chain fatty having from C | 12-04-2014 |
20140378539 | CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. | 12-25-2014 |
20150038567 | Cannabinoid Carboxylic Acids, Salts of Cannabinoid Carboxylic Acids, and the Production and Uses of Same - The invention relates to a compound selected from the group consisting of all stereoisomers and their mixtures of the compounds of general formulas (1)-(4), in which R | 02-05-2015 |
20150057341 | Composition with Pharmacological Effect for Vaporizing and Method - A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition. | 02-26-2015 |
20150057342 | COMPOSITIONS FOR COMBINED IMMEDIATE AND SUSTAINED RELEASE OF CANNABINOIDS, METHODS OF MANUFACTURE AND USE THEREOF - Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof. | 02-26-2015 |
20150105455 | WINTERIZED CRUDE CANNABIS EXTRACTS AND METHODS OF PREPARATION AND USE - The present technology relates to liquid compositions for use in a personal vaporizer. More particularly, the present technology relates to liquid compositions comprising winterized Cannabis extract, and to methods of administering vaporized winterized Cannabis extract to a subject by inhalation. | 04-16-2015 |
20150119456 | TRICYCLIC SULFONE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 04-30-2015 |
20150126595 | TRANSDERMAL CANNABINOID FORMULATIONS - The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia. | 05-07-2015 |
20150126596 | METHODS FOR PURIFYING TRANS-(-)-Delta9-TETRAHYDROCANNABINOL AND TRANS-(+)-Delta9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 05-07-2015 |
20150141501 | ULTRAPURE TETRAHYDROCANNABINOL-11-OIC ACIDS - This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis. | 05-21-2015 |
20150313867 | ANTI-TUMOURAL EFFECTS OF CANNABINOID COMBINATIONS - The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). | 11-05-2015 |
20150320720 | METHODS AND COMPOSITIONS FOR TREATING CANCER - This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof. | 11-12-2015 |
20150335590 | USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY - This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. | 11-26-2015 |
20150343071 | STABLE CANNABINOID FORMULATIONS - The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use. | 12-03-2015 |
20160002579 | SYSTEMS AND METHODS FOR CREATING A MIXED COCKTAIL DRINK - A flavored cube can be used to provide ingredients for mixing a cocktail and to keep the cocktail chilled without diluting the taste or potency of the cocktail. The flavored cube can be packaged in a variety of ways, including individually packaged units and/or kits that include a plurality of flavored cubes. | 01-07-2016 |
20160022630 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 01-28-2016 |
20160058731 | METHODS OF TREATING LIVER DISEASES - The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-03-2016 |
20160058866 | ALTERNATIVE SOLUTIONS FOR THE ADMINISTRATION OF CANNABIS DERIVED BOTANICAL PRODUCTS - Compositions comprising: (a) at least one polyvinylpyrrolidone/vinyl acetate copolymer that forms an open matrix network; and (b) at least one ingredient tetrahydrocannabinol and cannabidiol present within the open matrix network. | 03-03-2016 |
20160068321 | PHARMACEUTICAL FORMULATION - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. | 03-10-2016 |
20160106705 | CANNABIS EXTRACTS AND METHODS OF PREPARING AND USING SAME - The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from | 04-21-2016 |
20160130217 | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE - The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided. | 05-12-2016 |
20160136127 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR INCREASING RADIOSENSITVITY IN THE TREATMENT OF A BRAIN TUMOUR - The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma. | 05-19-2016 |
20160136128 | THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA - The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG. | 05-19-2016 |
20160158298 | MEDICAL CANNABIS LOZENGES AND COMPOSITIONS THEREOF - A method for optimizing the therapeutic effects provided by CBD on the one hand, and the psychoactive effects provided by THC on the other hand, in a sublingual medicament, the method includes the steps of obtaining a concentrated extract of | 06-09-2016 |
20160184258 | ORAL GASTROINTESTINAL DOSAGE FORM DELIVERY SYSTEM OF CANNABINOIDS AND/OR STANDARDIZED MARIJUANA EXTRACTS - An oral gastrointestinal dosage form of cannabinoids and/or standardized marijuana extracts in a self-emulsifying system operable to avoid hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery for promoting lymphatic transport. The oral gastrointestinal dosage form includes: (a) a pharmacologically active form of cannabinoids and/or standardized marijuana extracts; and (b) an oily medium consisting of: (i) one or more triglycerides formed from long chain fatty having from C | 06-30-2016 |
20160184259 | OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT - This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution. | 06-30-2016 |
20160184261 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 06-30-2016 |
20160199344 | METHODS FOR PURIFYING TRANS-(-)-.DELTA.9-TETRAHYDROCANNABINOL AND TRANS-(+)-.DELTA.9 TETRAHYDROCANNABINOL | 07-14-2016 |
20160250180 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY | 09-01-2016 |
20160250270 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL | 09-01-2016 |
20170231948 | Cannabinoid Alcoholic Drink | 08-17-2017 |
20180021435 | HYPOTONIC HYDROGEL FORMULATIONS FOR ENHANCED TRANSPORT OF ACTIVE AGENTS AT MUCOSAL SURFACES | 01-25-2018 |